LEtrozole (Femara®)







Printed: 13/May/2020

Name: Nationalit Gender/A	-		File #: Civil ID: DOB:	Ht (cm): Wt (Kg): BSA (m²):
Indication(s): HR +ve breast cancer, Neoadjuvant / Adjuvant / Palliative. Central line: □ Available □ NA Allergies: □ NKA □ Yes, specify;				
Standard Protocol:				
DRUG DOS		ADMINISTRATION		
LEtrozole 2.5		g PO daily To be taken at the same time every day, with or without food.		
 □ Adjuvant: Postmenopausal: Duration of LEtrozole treatment is 5 years. □ Extended adjuvant therapy: 5 years Tamoxifen followed by 5 years of LEtrozole. □ Palliative: To be continued until disease progression or intolerable toxicity. 				
Treatment Description:				
Cycle	Date	LEtrozole	Physician	Consultant
C#				
Important Notes: Reported grade 3/4 toxicities: None Hematological Non-Hematological If yes; Did it indicate hospitalization? Yes No Did it indicate chemo-delay for ≥ 7 days? Yes No Did it indicate dose reduction? Yes No Did it indicate G-CSF support? Yes No				